<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jamt</journal-id><journal-title-group><journal-title xml:lang="ru">Journal of Advanced Materials and Technologies</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Advanced Materials and Technologies</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2782-2192</issn><issn pub-type="epub">2782-2206</issn><publisher><publisher-name>ФГБОУ ВО «ТГТУ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17277/jamt.2024.04.pp.276-285</article-id><article-id custom-type="elpub" pub-id-type="custom">jamt-41</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Биологические материалы, наномедицина и новые технологии для клинического и медицинского применения</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Biological materials; nanomedicine, and novel technologies for clinical and medical applications</subject></subj-group></article-categories><title-group><article-title>Механизм взаимодействия компонентов нового лекарственного покрытия медицинских стентов на основе поливинилпирролидона с введенными углеродными нанотрубками и лекарственными препаратами</article-title><trans-title-group xml:lang="en"><trans-title>The mechanism of interaction of a new drug coating components for medical stents based on polyvinylpyrrolidone with introduced carbon nanotubes and drugs</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9486-2482</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Запороцкова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaporotskova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Запороцкова Ирина Владимировна, доктор физико-математических наук, директор института</p><p>пр. Университетский, 100, Волгоград, 400062</p></bio><bio xml:lang="en"><p>Irina V. Zaporotskova, D. Sc. (Phys. and Math.),Director of the Institute</p><p>100, Universitetskiy Av., Volgograd, 400062</p></bio><email xlink:type="simple">irinazaporotskova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2695-1213</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чешева</surname><given-names>М. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Chesheva</surname><given-names>M. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чешева Мария Федоровна, ассистент</p><p>пр. Университетский, 100, Волгоград, 400062</p></bio><bio xml:lang="en"><p>Mariia F. Chesheva, Assistan</p><p>100, Universitetskiy Av., Volgograd, 400062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Элбакян</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Elbakyan</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Элбакян Лусине Самвеловна, кандидат физико-математических наук, доцент</p><p>пр. Университетский, 100, Волгоград, 400062</p></bio><bio xml:lang="en"><p>Lusine S. Elbakyan, Cand. Sc. (Phys. and Math.),Associate Professor</p><p>100, Universitetskiy Av., Volgograd, 400062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Волгоградский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State University (VolSU)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2026</year></pub-date><volume>9</volume><issue>4</issue><fpage>276</fpage><lpage>285</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Запороцкова И.В., Чешева М.Ф., Элбакян Л.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Запороцкова И.В., Чешева М.Ф., Элбакян Л.С.</copyright-holder><copyright-holder xml:lang="en">Zaporotskova I.V., Chesheva M.F., Elbakyan L.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://jamt.elpub.ru/jour/article/view/41">https://jamt.elpub.ru/jour/article/view/41</self-uri><abstract><p>Практически все используемые в России стенты с лекарственными покрытиями произведены за рубежом и имеют высокую стоимость, что не может удовлетворять потребностям российских пациентов и их финансовым возможностям. В связи с этим актуальным является поиск и разработка новых типов покрытий медицинских стентов, а также налаживание их производства в РФ. Необходимо создание тонкопленочных лекарственных покрытий стентов с увеличенным временем испускания лекарственного препарата для лечения различных заболеваний. В качестве компонента, обеспечивающего пролонгированную и дозированную десорбцию лекарственного препарата с поверхности стента, лучше всего использовать полимерный носитель. В работе исследована возможность применения перспективного материала современности – углеродных нанотрубок – в качестве компонента лекарственного покрытия медицинского стента, который обеспечит не только улучшение физико-механических свойств покрытия, но и пролонгированное действие лекарственного препарата за счет увеличения времени его десорбции. Выполнены теоретические исследования механизмов взаимодействия компонентов лекарственных покрытий стентов на основе биополимера поливинилпирролидона, в состав которых входят лекарственные препараты (тегафур, дексаметазон) и углеродные нанотрубки. Исследования выполнены в рамках квантово-химического расчетного метода теории функционала плотности (DFT), который широко используется во всем мире для расчета наносистем.</p></abstract><trans-abstract xml:lang="en"><p>Almost all stents with medicinal coatings used in Russia are manufactured abroad and have a high cost, which cannot meet the needs of Russian patients and their financial capabilities. The search and development of new types of medical stent coatings, as well as the establishment of their production in the Russian Federation is relevant. It is necessary to create thin-film drug coatings of stents with an extended time of drug emission for the treatment of various diseases. As a component providing prolonged and dosed desorption of the drug from the surface of the stent, it is best to use a carrier polymer. The paper investigates the possibility of using a promising modern material – carbon nanotubes – as a component of the medicinal coating of a medical stent, which will provide not only an improvement in the physical and mechanical properties of the coating, but also a prolonged effect of the drug by increasing its desorption time. Theoretical studies on the mechanisms of creating drug coatings for stents based on the polyvinylpyrrolidone copolymer, which include drugs (tegafur, dexamethasone) and carbon nanotubes, have been carried out. The quantum chemical calculation method – the density functional theory DFT, which is applied worldwide for calculating nanosystems, was used for research.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>медицинские стенты</kwd><kwd>лекарственное покрытие</kwd><kwd>углеродные нанотрубки</kwd><kwd>тегафур</kwd><kwd>дексаметазон</kwd><kwd>поливинилпирролидон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>medical stents</kwd><kwd>drug coating</kwd><kwd>carbon nanotubes</kwd><kwd>tegafur</kwd><kwd>dexamethasone</kwd><kwd>polyvinylpyrrolidone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Seo EH, Na K. Polyurethane membrane with porous surface for controlled drug release in drug eluting stent. Biomaterials Research. 2014;18(1):15. DOI:10.1186/2055-7124-18-15</mixed-citation><mixed-citation xml:lang="en">Seo EH, Na K. Polyurethane membrane with porous surface for controlled drug release in drug eluting stent. Biomaterials Research. 2014;18(1):15. DOI:10.1186/2055-7124-18-15</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome: Coronary Artery Disease. 2004;15(6):313-318. DOI:10.1097/00019501-200409000-00003</mixed-citation><mixed-citation xml:lang="en">Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome: Coronary Artery Disease. 2004;15(6):313-318. DOI:10.1097/00019501-200409000-00003</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mir SA, Hamid L, Bader GN, Shoaib A, et al. Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review. Molecules. 2022;27(19):6608. DOI:10.3390/molecules27196608</mixed-citation><mixed-citation xml:lang="en">Mir SA, Hamid L, Bader GN, Shoaib A, et al. Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review. Molecules. 2022;27(19):6608. DOI:10.3390/molecules27196608</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Paul A, Shao W, Shum-Tim D, Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles. Biomaterials. 2012;33(30):7655-7664. DOI:10.1016/j.biomaterials.2012.06.096</mixed-citation><mixed-citation xml:lang="en">Paul A, Shao W, Shum-Tim D, Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles. Biomaterials. 2012;33(30):7655-7664. DOI:10.1016/j.biomaterials.2012.06.096</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Patra JK, Das G, Fraceto LF, Campos EVR, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1):71. DOI:10.1186/s12951-018-0392-8</mixed-citation><mixed-citation xml:lang="en">Patra JK, Das G, Fraceto LF, Campos EVR, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1):71. DOI:10.1186/s12951-018-0392-8</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hua S, De Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology. 2018;9:790. DOI:10.3389/fphar.2018.00790</mixed-citation><mixed-citation xml:lang="en">Hua S, De Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology. 2018;9:790. DOI:10.3389/fphar.2018.00790</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zvonareva DA, Zaporotskova IV, An EE, Chesheva MF. Investigation of the possibility of creating a drug coating for coronary stents based on chitosan and heparin. Interaction of ultrahigh frequency, terahertz and optical radiation with semiconductor micro- and nanostructures, metamaterials and biological objects: Collection of articles of the ninth All-Russian Scientific School-seminar, Saratov, May 24, 2022. Saratov: "Saratov source" Publ. house; 2022. p. 223-226.</mixed-citation><mixed-citation xml:lang="en">Zvonareva DA, Zaporotskova IV, An EE, Chesheva MF. Investigation of the possibility of creating a drug coating for coronary stents based on chitosan and heparin. Interaction of ultrahigh frequency, terahertz and optical radiation with semiconductor micro- and nanostructures, metamaterials and biological objects: Collection of articles of the ninth All-Russian Scientific School-seminar, Saratov, May 24, 2022. Saratov: "Saratov source" Publ. house; 2022. p. 223-226.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zaporotskova IV, Suchkov SG, Boroznin SV, Zvonareva DA, et al. Study of the possibility of creating a drug coating of biliary stents based on the copolymer "polylactic acid - polycaprolactone" modified with carbon nanotubes and doxorubicin. NBI technologies. 2023;17(2):18-26. DOI :10.15688/NBIT.jvolsu.2023.2.3 (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Zaporotskova IV, Suchkov SG, Boroznin SV, Zvonareva DA, et al. Study of the possibility of creating a drug coating of biliary stents based on the copolymer "polylactic acid - polycaprolactone" modified with carbon nanotubes and doxorubicin. NBI technologies. 2023;17(2):18-26. DOI :10.15688/NBIT.jvolsu.2023.2.3 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yetisgin AA, Cetinel S, Zuvin M, Kosar A, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. DOI: 10.3390/molecules25092193</mixed-citation><mixed-citation xml:lang="en">Yetisgin AA, Cetinel S, Zuvin M, Kosar A, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. DOI: 10.3390/molecules25092193</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X, Liu J, Li X, Li F, et al. Trastuzumabcoated nanoparticles loaded with docetaxel for breast cancer therapy. Dose-Response. 2019;17(3):155932581987258. DOI:10.1177/1559325819872583</mixed-citation><mixed-citation xml:lang="en">Zhang X, Liu J, Li X, Li F, et al. Trastuzumabcoated nanoparticles loaded with docetaxel for breast cancer therapy. Dose-Response. 2019;17(3):155932581987258. DOI:10.1177/1559325819872583</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Y, Zhou Y, Liu L, Xu Y, et al. Nanoparticlebased drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences. 2020;7:193. DOI:10.3389/fmolb.2020.00193</mixed-citation><mixed-citation xml:lang="en">Yao Y, Zhou Y, Liu L, Xu Y, et al. Nanoparticlebased drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences. 2020;7:193. DOI:10.3389/fmolb.2020.00193</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yokoyama S, Tamaru S, Tamaki S, Nakanishi D, et al. Genetic risk factors associated with antiemetic efficacy of palonosetron, aprepitant, and dexamethasone in japanese breast cancer patients treated with anthracyclinebased chemotherapy. Clinical Breast Cancer. 2018;18(2):e157-e165. DOI:10.1016/j.clbc.2017.05.013</mixed-citation><mixed-citation xml:lang="en">Yokoyama S, Tamaru S, Tamaki S, Nakanishi D, et al. Genetic risk factors associated with antiemetic efficacy of palonosetron, aprepitant, and dexamethasone in japanese breast cancer patients treated with anthracyclinebased chemotherapy. Clinical Breast Cancer. 2018;18(2):e157-e165. DOI:10.1016/j.clbc.2017.05.013</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen P-H, Jhou H-J, Chung C-H, Wu Y-Y, et al. Benefit of uracil–tegafur used as a postoperative adjuvant chemotherapy for stage IIA colon cancer. Medicina. 2022;59(1):10. DOI:10.3390/medicina59010010</mixed-citation><mixed-citation xml:lang="en">Chen P-H, Jhou H-J, Chung C-H, Wu Y-Y, et al. Benefit of uracil–tegafur used as a postoperative adjuvant chemotherapy for stage IIA colon cancer. Medicina. 2022;59(1):10. DOI:10.3390/medicina59010010</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Voronov VK, Kim D, Yanushkin AS, Gerashchenko LA. Properties and application of nanomaterials. Moscow: TNT LLC; 2012. 220 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Voronov VK, Kim D, Yanushkin AS, Gerashchenko LA. Properties and application of nanomaterials. Moscow: TNT LLC; 2012. 220 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kedik SA, Zhavoronok ES, Sedishev IP, Panov AV, et al. Polymers for sustained drug delivery systems with prolonged action (review). Promising synthetic and natural polymers. Razrabotka i registratsiya lekarstvennykh sredstv. 2013;2(3):18-26. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kedik SA, Zhavoronok ES, Sedishev IP, Panov AV, et al. Polymers for sustained drug delivery systems with prolonged action (review). Promising synthetic and natural polymers. Razrabotka i registratsiya lekarstvennykh sredstv. 2013;2(3):18-26. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Alekseev KV, Gritskova IA, Kedik SA. Polymers for pharmaceutical technology. Moscow: IFT Publ. house; 2011. 512 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Alekseev KV, Gritskova IA, Kedik SA. Polymers for pharmaceutical technology. Moscow: IFT Publ. house; 2011. 512 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Phan DC, Goodwin DG, Frank BP, Bouwer EJ, et al. Biodegradability of carbon nanotube/polymer nanocomposites under aerobic mixed culture conditions. Science of the Total Environment. 2018;639:804-814. DOI: 10.1016/j.scitotenv.2018.05.137</mixed-citation><mixed-citation xml:lang="en">Phan DC, Goodwin DG, Frank BP, Bouwer EJ, et al. Biodegradability of carbon nanotube/polymer nanocomposites under aerobic mixed culture conditions. Science of the Total Environment. 2018;639:804-814. DOI: 10.1016/j.scitotenv.2018.05.137</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zaporotskova I, Kalinichenko V, Kozhitov L, Zaporotskov P, Kislova T. On the influence of carbon nanotubes on the physical and mechanical properties of polypropylene. NBI Technologies. 2021;15(2):27-36. DOI: 10.15688/NBIT.jvolsu.2021.2.5 (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Zaporotskova I, Kalinichenko V, Kozhitov L, Zaporotskov P, Kislova T. On the influence of carbon nanotubes on the physical and mechanical properties of polypropylene. NBI Technologies. 2021;15(2):27-36. DOI: 10.15688/NBIT.jvolsu.2021.2.5 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Valeeva AA, Dekhtyar TF. Carbon nanotubes in medicine. Condensed matter physics and its applications: Proceedings of the IV International Scientific and Practical Conference, Sterlitamak, September 22-24, 2022. Sterlitamak: Bashkir State UniversityPubl. house; 2022. p. 467-469. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Valeeva AA, Dekhtyar TF. Carbon nanotubes in medicine. Condensed matter physics and its applications: Proceedings of the IV International Scientific and Practical Conference, Sterlitamak, September 22-24, 2022. Sterlitamak: Bashkir State UniversityPubl. house; 2022. p. 467-469. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chernozatonsky LA, Sorokin PB. Carbon nanotubes: from fundamental research to nanotechnology. Moscow: Nauka; 2007. p. 154-174. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Chernozatonsky LA, Sorokin PB. Carbon nanotubes: from fundamental research to nanotechnology. Moscow: Nauka; 2007. p. 154-174. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zaporotskova IV. Carbon and non-carbon nanomaterials and composite structures based on them: structure and electronic properties. Volgograd: Volgograd State University Publ. house; 2009. 488 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Zaporotskova IV. Carbon and non-carbon nanomaterials and composite structures based on them: structure and electronic properties. Volgograd: Volgograd State University Publ. house; 2009. 488 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ermachenkova KY, Simakova EK. The structure of the cytostatic drugs group (classification). Innovations in science and practice: A collection of scientific articles based on the materials of the XII International Scientific and Practical Conference, Ufa, May 05, 2023. Volume Part 3. Ufa: Bulletin of Science LLC; 2023. p. 14-20. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Ermachenkova KY, Simakova EK. The structure of the cytostatic drugs group (classification). Innovations in science and practice: A collection of scientific articles based on the materials of the XII International Scientific and Practical Conference, Ufa, May 05, 2023. Volume Part 3. Ufa: Bulletin of Science LLC; 2023. p. 14-20. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cytostatics. Available from: https://www.euroonco.ru/preparations-from-a-z/citostatiki [Accessed 20 May 2024] (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Cytostatics. Available from: https://www.euroonco.ru/preparations-from-a-z/citostatiki [Accessed 20 May 2024] (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Semenov NN, Vakhabova YuV. The role of the drug tegafur/uracil in the treatment of malignant tumors. Vmeste protiv raka: vracham vsekh spetsial′nostey. 2008;(1):20-25. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Semenov NN, Vakhabova YuV. The role of the drug tegafur/uracil in the treatment of malignant tumors. Vmeste protiv raka: vracham vsekh spetsial′nostey. 2008;(1):20-25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Romanov BK, Dmitrieva NB, Zatsepilova TA. Antitumor drugs. Rossiyskiy meditsinskiy zhurnal. 2018;24(3):146-150. DOI:10.18821/0869-2106-2018-24-3-146-150 (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Romanov BK, Dmitrieva NB, Zatsepilova TA. Antitumor drugs. Rossiyskiy meditsinskiy zhurnal. 2018;24(3):146-150. DOI:10.18821/0869-2106-2018-24-3-146-150 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kakora S, Ulanova T, Kotlyarov A, Korniletsky I, et al. Experience of using antimetabolic agents in the therapy of antitumor diseases. Mezhdunarodnyy nauchnoissledovatel′skiy zhurnal. 2023;4(130):52. DOI:10.23670/ IRJ.2023.130.35 (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kakora S, Ulanova T, Kotlyarov A, Korniletsky I, et al. Experience of using antimetabolic agents in the therapy of antitumor diseases. Mezhdunarodnyy nauchnoissledovatel′skiy zhurnal. 2023;4(130):52. DOI:10.23670/ IRJ.2023.130.35 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Order of the Ministry of Health of the Russian Federation No. 103n dated February 28, 2019 "On approval of the procedure and deadlines for the development of clinical recommendations, their revision, the standard form of clinical recommendations and requirements for their structure, composition and scientific validity included in clinical recommendations", Appendix A3 "Reference materials, including compliance with indications for use and contraindications, methods of application and doses of medicines, instructions for the use of the drug". Available from: http://publication. pravo.gov.ru [Accessed 2 June 2024] (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Order of the Ministry of Health of the Russian Federation No. 103n dated February 28, 2019 "On approval of the procedure and deadlines for the development of clinical recommendations, their revision, the standard form of clinical recommendations and requirements for their structure, composition and scientific validity included in clinical recommendations", Appendix A3 "Reference materials, including compliance with indications for use and contraindications, methods of application and doses of medicines, instructions for the use of the drug". Available from: http://publication. pravo.gov.ru [Accessed 2 June 2024] (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The New England Journal of Medicine. 2000;342(21):59. DOI:10.1056/NEJM200005253422102</mixed-citation><mixed-citation xml:lang="en">Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The New England Journal of Medicine. 2000;342(21):59. DOI:10.1056/NEJM200005253422102</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Harousseau JL, Attal M, Leleu X, Troncy J, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498-505.</mixed-citation><mixed-citation xml:lang="en">Harousseau JL, Attal M, Leleu X, Troncy J, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498-505.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Koch WA. Chemist’s guide to density functional theory. Weinheim: Wiley-VCH; 2001. p. 19-28.</mixed-citation><mixed-citation xml:lang="en">Koch WA. Chemist’s guide to density functional theory. Weinheim: Wiley-VCH; 2001. p. 19-28.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Elbakyan LS. Quantum chemical calculations using the GAUSSIAN software package and the GAUSSVIEW graphic. Volgograd: Volgograd State University Publ. house; 2022. 79 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Elbakyan LS. Quantum chemical calculations using the GAUSSIAN software package and the GAUSSVIEW graphic. Volgograd: Volgograd State University Publ. house; 2022. 79 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. A new ultrathin medicinal coating of medical stents: the mechanism of interaction and application technology. Methods of computer diagnostics in biology and medicine - 2021: collection of articles of the All-Russian School Seminar, Saratov, November 19, 2021. Saratov: "Saratovsky Istochnik" Publ. house; 2021. p. 49-52.</mixed-citation><mixed-citation xml:lang="en">Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. A new ultrathin medicinal coating of medical stents: the mechanism of interaction and application technology. Methods of computer diagnostics in biology and medicine - 2021: collection of articles of the All-Russian School Seminar, Saratov, November 19, 2021. Saratov: "Saratovsky Istochnik" Publ. house; 2021. p. 49-52.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zvonareva DA, An EE, Zaporotskova IV. New ultrathin medical coating of PVP-based medical biliary stents with addition of carbon nanotubes. AIP Conference Proceedings: The VII International Young Researchers’ Conference – Physics, Technology, Innovations (PTI-2020), 18 May 2020. Ekaterinburg: AIP Publishing. 2020;2313:080037. DOI: 10.1063/5.0032234</mixed-citation><mixed-citation xml:lang="en">Zvonareva DA, An EE, Zaporotskova IV. New ultrathin medical coating of PVP-based medical biliary stents with addition of carbon nanotubes. AIP Conference Proceedings: The VII International Young Researchers’ Conference – Physics, Technology, Innovations (PTI-2020), 18 May 2020. Ekaterinburg: AIP Publishing. 2020;2313:080037. DOI: 10.1063/5.0032234</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. Interaction mechanism and technology for application of new ultra-thin drug coating of medical biliary stents. NBI Technologies. 2022;(1):33-38. DOI:10.15688/NBIT.jvolsu.2022.1.6 (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Zvonareva DA, An EE, Chesheva MF, Zaporotskova IV. Interaction mechanism and technology for application of new ultra-thin drug coating of medical biliary stents. NBI Technologies. 2022;(1):33-38. DOI:10.15688/NBIT.jvolsu.2022.1.6 (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
